The Invesco S&P 500 Concentrated QVM ETF recently changed strategies, now opting to hold 100 stocks based on their combined ...

Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and ...

Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative ...

Although plasma factor H-related protein 5 (FHR5) levels alone were not a significant predictor of ESKD, glomerular FHR5 deposition strongly predicted progression to ESKD.

InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)The Company is assessing the most efficient de ...

Fear Factor is back — with a Big Brother-y twist. Entertainment Weekly can exclusively premiere the first trailer for Fear Factor: House of Fear, the new iteration of the skin-crawling reality ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease caused by problems in the body's complement system, which normally helps fight infections. It damages tiny filters in your kidneys called ...

Findings suggest that the complement system plays a role in the onset of acute kidney injury in critically ill patients. Urinary Ba, a fragment of complement factor B, may be a biomarker and mediator ...

A recently granted patent (Publication Number: US11926617B2) discloses a method for treating disorders mediated by complement factor D. The method involves administering a compound of a specific ...

The patent application US20240018515A1 discloses a double-stranded ribonucleic acid (dsRNA) designed to inhibit the expression of complement factor B (CFB) in cells. The dsRNA consists of a sense ...